We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs
Read MoreHide Full Article
Key Takeaways
SuperFlex expands prenatal and preeclampsia testing access for small and mid-sized labs and clinics.
Revvity's automated benchtop system runs up to 60 tests per hour, with results in as little as 14 minutes.
SuperFlex will launch in CE-marked markets first, with Asia-Pacific expansion planned for late 2026.
Revvity, Inc. (RVTY - Free Report) recently announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex initially will be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.
Per management, the SuperFlex system represents a significant addition to Revvity’s prenatal screening portfolio by addressing financial and operational barriers associated with in-house testing. The company believes the platform’s accessibility, simplicity and flexible throughput can enable this potentially life-saving testing to be more accessible to women, irrespective of where they receive care.
Likely Trend of RVTY Stock Following the News
Shares of RVTY have gained 1.6% since the announcement on Monday. Year to date, the stock rose 21.8% compared with the industry’s 1.2% growth and the S&P 500’s 12.7% gain.
The launch of SuperFlex is expected to strengthen Revvity’s position in the prenatal screening and reproductive health market. By targeting small and mid-sized laboratories that may not have access to high-throughput centralized testing, the platform could expand the company’s addressable market and support broader adoption of its prenatal screening solutions. Growing demand for preeclampsia screening, along with planned expansion into Asia-Pacific, could create additional opportunities for Revvity to increase instrument placements, consumables demand and recurring revenue over the long term.
RVTY currently has a market capitalization of $12.91 billion.
Image Source: Zacks Investment Research
More on the News
SuperFlex is a fully automated benchtop immunoanalyzer that uses chemiluminescence immunoassay (CLIA) technology and features a cartridge-based design with 24 sample positions. The system can process up to 60 tests per hour, supports continuous sample loading and delivers initial results in as little as 14 minutes. Its flexible workflow allows laboratories to process samples as needed for both urgent and routine testing.
SuperFlex supports in-house screening for preeclampsia, a condition affecting 2% to 8% of pregnancies, while offering first- and second-trimester biochemical prenatal screening. It offers an accessible solution with lower instrument costs, annual maintenance and no reagent wastage at low sample volumes. The system combines full automation with a user-friendly design that can reduce training requirements and integrates with Revvity’s LifeCycle software.
Revvity’s LifeCycle software is a comprehensive informatics and risk-calculation solution that supports maternal and fetal health screening. Together, SuperFlex and LifeCycle provide a decentralized prenatal screening solution for streamlined risk assessment and LIMS data transfer. By enabling cost-effective, decentralized testing, SuperFlex can help laboratories and clinics bring timely prenatal screening closer to patients.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the global preeclampsia diagnostics market is predicted to be valued at $1.33 billion in 2026 and is expected to witness a CAGR of 3.1% through 2035.
Factors like the rising awareness of maternal health, technological advancements in point-of-care testing, and increasing prenatal screening initiatives are boosting the market’s growth.
Other News
Revvity recently announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support large-volume clinical laboratories performing latent tuberculosis (TB) testing. The platform is targeted for launch in the second half of 2027.
Revvity recently launched Signals for Startups, a new program to help early-stage biotechnology companies establish scalable digital informatics capabilities from the earliest stages of research.
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Cardinal Health (CAH - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, reported a fourth-quarter fiscal 2026 adjusted EPS of $2.91, which beat the Zacks Consensus Estimate by 20.3%. Revenues of $63.67 billion missed the Zacks Consensus Estimate by 2.9%.
CAH has an estimated long-term earnings growth rate of 13.5%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.7%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
View the Zacks #1 Rank List
Image: Bigstock
Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs
Key Takeaways
Revvity, Inc. (RVTY - Free Report) recently announced the launch of the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Purpose-built for small to mid-sized laboratories and clinics, the platform is intended to bring reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex initially will be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.
Per management, the SuperFlex system represents a significant addition to Revvity’s prenatal screening portfolio by addressing financial and operational barriers associated with in-house testing. The company believes the platform’s accessibility, simplicity and flexible throughput can enable this potentially life-saving testing to be more accessible to women, irrespective of where they receive care.
Likely Trend of RVTY Stock Following the News
Shares of RVTY have gained 1.6% since the announcement on Monday. Year to date, the stock rose 21.8% compared with the industry’s 1.2% growth and the S&P 500’s 12.7% gain.
The launch of SuperFlex is expected to strengthen Revvity’s position in the prenatal screening and reproductive health market. By targeting small and mid-sized laboratories that may not have access to high-throughput centralized testing, the platform could expand the company’s addressable market and support broader adoption of its prenatal screening solutions. Growing demand for preeclampsia screening, along with planned expansion into Asia-Pacific, could create additional opportunities for Revvity to increase instrument placements, consumables demand and recurring revenue over the long term.
RVTY currently has a market capitalization of $12.91 billion.
Image Source: Zacks Investment Research
More on the News
SuperFlex is a fully automated benchtop immunoanalyzer that uses chemiluminescence immunoassay (CLIA) technology and features a cartridge-based design with 24 sample positions. The system can process up to 60 tests per hour, supports continuous sample loading and delivers initial results in as little as 14 minutes. Its flexible workflow allows laboratories to process samples as needed for both urgent and routine testing.
SuperFlex supports in-house screening for preeclampsia, a condition affecting 2% to 8% of pregnancies, while offering first- and second-trimester biochemical prenatal screening. It offers an accessible solution with lower instrument costs, annual maintenance and no reagent wastage at low sample volumes. The system combines full automation with a user-friendly design that can reduce training requirements and integrates with Revvity’s LifeCycle software.
Revvity’s LifeCycle software is a comprehensive informatics and risk-calculation solution that supports maternal and fetal health screening. Together, SuperFlex and LifeCycle provide a decentralized prenatal screening solution for streamlined risk assessment and LIMS data transfer. By enabling cost-effective, decentralized testing, SuperFlex can help laboratories and clinics bring timely prenatal screening closer to patients.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the global preeclampsia diagnostics market is predicted to be valued at $1.33 billion in 2026 and is expected to witness a CAGR of 3.1% through 2035.
Factors like the rising awareness of maternal health, technological advancements in point-of-care testing, and increasing prenatal screening initiatives are boosting the market’s growth.
Other News
Revvity recently announced the development of the T-SPOT A201, a next-generation high-throughput automated platform designed to support large-volume clinical laboratories performing latent tuberculosis (TB) testing. The platform is targeted for launch in the second half of 2027.
Revvity recently launched Signals for Startups, a new program to help early-stage biotechnology companies establish scalable digital informatics capabilities from the earliest stages of research.
Revvity Inc. Price
Revvity Inc. price | Revvity Inc. Quote
RVTY’s Zacks Rank & Key Picks
Revvity currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Cardinal Health (CAH - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, reported a fourth-quarter fiscal 2026 adjusted EPS of $2.91, which beat the Zacks Consensus Estimate by 20.3%. Revenues of $63.67 billion missed the Zacks Consensus Estimate by 2.9%.
CAH has an estimated long-term earnings growth rate of 13.5%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.7%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.